logo
Share SHARE
FONT-SIZE Plus   Neg

Lonza, Agennix Ink Deal For Production Of Talactoferrin - Quick Facts

Lonza Group AG (LZAGF.PK) said it entered into an agreement with Agennix AG for the production of Agennix's first-in-class oral Dendritic Cell Mediated Immunotherapy, talactoferrin, currently in Phase III testing for the treatment of non-small cell lung cancer.

As per the agreement, Lonza will produce commercial material at its microbial manufacturing facility in Kourim, Czech Republic. Lonza stated that the agreement initiates the process needed to be able to ultimately seek approval for Lonza as a second manufacturer of talactoferrin after the initial commercial launch.

Rajesh Malik, chief medical officer and Management Board member of Agennix, said, "We are pleased to enter this agreement with Lonza, which has extensive experience manufacturing biologics on a commercial scale. In anticipation of positive Phase III data and a potential product approval, it is important that we have more than one manufacturer in place to ensure we can meet anticipated commercial demand and that we have security of supply."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
British lender Lloyds Banking Group Plc. Friday reported higher profit in its first half, benefited by increased net interest income and margin as well as lower impairment. Looking ahead, the company lifted its net interest margin forecast. Amgen reported an increase in second-quarter profit, driven by sales of arthritis drug Enbrel and osteoporosis treatments Xgeva and Prolia, and improved margins. Both earnings and sales topped Wall Street estimates. Electronic Arts Inc. (EA) on Thursday reported an increase in profit for the first quarter, reflecting continued strong digital revenues, with both earnings and revenues topping Wall Street estimates. However, shares of the company fell over 4 percent, after having detailed a weak outlook. Redwood...
comments powered by Disqus
Follow RTT